CLAIMS

1. A crystalline form of Compound A,

wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

2. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 2.

3. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 4.

4. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 9.

5. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 11.

6. A solid state form of Compound A comprising two or more of the crystalline forms of claims 2-5.

7. The crystalline form of any one of claims 2-5, wherein the crystalline form is substantially free of the other solid state forms of Compound A.

8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and ~~a~~the crystalline form of ~~Compound A~~any one of claims 1-7.

~~9. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 2.~~

~~10. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 4.~~

~~11. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 9.~~

~~12. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 11.~~

~~13~~9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier and/or diluent and a mixture of two or more crystalline forms of Compound A, wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

~~14~~10. ~~A method of treating a seizure disorder in a human, wherein the method comprises administering a therapeutically effective amount of a~~The crystalline form of ~~Compound~~

~~A~~any one of claims 1-7 for use in the treatment of a seizure disorder in a ~~to the~~ human in need thereof.

~~15. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 2.~~

~~16. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 4.~~

~~17. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 9.~~

~~18. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 11.~~

~~19~~11. ~~A method of treating a seizure disorder in a human, wherein the method comprises administering a therapeutically effective amount of a~~A mixture of two or more crystalline forms of Compound A for use in the treatment of a seizure disorder in a~~to the~~ human in need thereof, wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

~~20~~12. A method of preparing a crystalline form of Compound A from another crystalline form of Compound A., wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

~~21~~13. A method of preparing a pharmaceutical composition comprising a pharmaceutical excipient and a crystalline form of Compound A, the method comprising combining the crystalline form of ~~Compound A~~any one of claims 1-7 with the pharmaceutical excipient to form the pharmaceutical composition.

~~22~~14. The ~~method of any one of claims 14-19~~crystalline form or mixture of crystalline forms for use of claim 10 or 11, wherein the crystalline form or mixture of crystalline forms ~~of Compound A~~ is administered to the human from between 30 minutes before to 2 hours after eating a meal.

~~23~~15. The ~~method of claim 22~~crystalline form or mixture of crystalline forms for use of 14, wherein the crystalline form or mixture of crystalline forms ~~of Compound A~~ is administered during a meal or within 15 minutes after eating a meal.

~~24~~16. Use of ~~a~~the crystalline form of ~~Compound A~~any one of claims 1-7 in the manufacture of a medicament for treating a seizure disorder in a human in need thereof.

~~25. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 2.~~

~~26. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 4.~~

~~27. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 9.~~

~~28. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 11.~~

~~29~~17. Use of a mixture of two or more crystalline forms of Compound A in the manufacture of a medicament for treating a seizure disorder in a human in need thereof.

~~30~~18. The use of ~~any one of claims 24-29~~claim 16 or 17, wherein the human is treated with the crystalline form of Compound A from between 30 minutes before to 2 hours after eating a meal.

~~31~~19. The use of claim ~~30~~18, wherein the human is treated with the crystalline form of Compound A during a meal or within 15 minutes after eating a meal.

20. A solid amorphous form of Compound A,

wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

21. A pharmaceutical composition comprising the solid amorphous form of claim 20 and a pharmaceutically acceptable excipient.

22. A method of preparing the pharmaceutical composition of claim 21, the method comprising combining the solid amorphous form of Compound A with the pharmaceutical excipient thereby forming the pharmaceutical composition.

23. A method of preparing the solid amorphous form of claim 20, comprising heating a crystalline form of Compound A, whereby said heating results in formation of the solid amorphous form of Compound A.

24. The method of claim 23, wherein said heating comprises heating the crystalline form of Compound A to at least 170° C.

25. The method of claim 24, wherein said heating comprises heating the crystalline form of Compound A to at least 180° C.

26 The method of claim 25, wherein said heating comprises heating the crystalline form of Compound A to at least 190° C.

27. The method of claim 24, further comprising cooling the Compound A to 25° C.

28. The method of claim 25, further comprising cooling the Compound A to 25° C.

29. The method of claim 26, further comprising cooling the Compound A to 25° C.

30. Use of a solid amorphous form of Compound A in the manufacture of a medicament for treating a seizure disorder in a human in need thereof,

wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

31. The use claim 30, wherein the solid amorphous form is administered to the human from between 30 minutes before to 2 hours after eating a meal.

32. The use of claim 31, wherein the solid amorphous form is administered during a meal or within 15 minutes after eating a meal.